It could be seen that VEGF expression was enhanced in endometrial carcinoma cells that overexpressed ATAD2. Also, VEGF expression was decreased in endometrial carcinoma cells in which ATAD2 was knocked down. This evidence concerns the gene ATAD2 and endometrial carcinoma.